SAINT PAUL, Minn., Aug. 29, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today reported financial results for the third quarter ended July 31, 2013.
Third Quarter Highlights:
Third quarter fiscal 2013 total revenues increased 15% to $7.9 million, compared to $6.9 million in the fiscal 2012 third quarter. Domestic 2013 third quarter sales increased 12% to $6.3 million, compared to $5.6 million in the 2012 third quarter, while international sales increased 29% to $1.6 million from $1.3 million in last year's third quarter, due primarily to sales improvements in Canada and Latin America. Third quarter Group Purchasing Organization ("GPO") sales increased 21% to $4.3 million, compared to $3.6 million in the prior year's third quarter.
Third quarter equipment, supplies and accessories sales totaled $6.6 million, an increase of 12.5%, compared to $5.9 million during last year's third quarter. Service revenues for the third quarter totaled $1.3 million, compared to $1.0 million during last year's third quarter. The Attachment Rate, which reflects the percentage of Extended Service Contracts added at the point of sale to customer equipment purchases, was 25.7% for the fiscal 2013 third quarter, compared to 2.7% for the same period last year. Backlog at July 31, 2013 was $709,000, and has steadily improved over the past nine months from $541,000 at the end of the 2013 second quarter and $415,000 at the end of the 2012 fourth quarter.
Gross margin for the quarter was 55.4%, compared to 53.7% in the 2012 third quarter. Gross margin for equipment, supplies and accessories was 52.3% for the quarter, compared to 51.8% in the prior year's quarter. Gross margin for services increased to 70.8% for the quarter, compared to 65.3% for the prior year's quarter, primarily as a result of improved pricing and service mix.
Third quarter 2013 general and administrative expenses totaled $973,000, or 12.3% of revenue, compared to $913,000, or 13.2% of revenue in the comparable quarter last year. Sales and marketing expenses were $2.2 million, or 27.1% of revenue, compared to $2.1 million, or 30.9% of revenue in the 2012 third quarter. Research and development expenses were $591,000, or 7.5% of revenue, compared to $825,000, or 12.0% of revenue in last year's third quarter. This decrease is due primarily to expense reductions attributed to management level personnel changes and the conversion of consultant services to full-time, internal personnel. Year to date, the Company has invested approximately $1.3 million in new research and product development initiatives. During the quarter, the Company capitalized $153,000 of software development expenses, compared to $216,000 for the same quarter last year. Even though research and development expenses have decreased, the Company continues to invest in new product development to ensure that its future product pipeline remains robust.
Third quarter operating income improved to $669,000, compared to an operating loss of $276,000 in the 2012 third quarter. For the 2013 third quarter, the Company reported net income of $652,000, or $0.16 per diluted share, versus a net loss of $133,000, or ($0.03) per diluted share, in the 2012 third quarter.
Gregg O. Lehman, Ph D., president and chief executive officer of MGC Diagnostics, said, "I am pleased to report that we generated solid double-digit revenue growth and achieved the highest quarterly profit since the first quarter of fiscal 2007. We grew across most revenue categories and geographies, with domestic and international revenue increasing 12% and 29%, respectively. Equipment, supplies and accessories revenue increased 12% and service revenue increased 29%. Gross margins improved for all revenue sources and operating expenses as a percent of revenue fell to 46.9% compared to 57.8% for last year's third quarter. These results are in line with our internal expectations and we look forward to continued improvements during the quarters ahead."
"Our initiative to obtain new sales from accounts held by our competition gained additional traction during the third quarter," continued Dr. Lehman. "For the first nine months of the fiscal year, we have converted 71 accounts that previously used equipment provided by our competitors, representing approximately $3.9 million of revenue. We are pleased with this result because a large part of our growth strategy was to gain market share."
"We were also happy with the Attachment Rate of new extended service contracts during the quarter. These contracts, which have terms ranging from one to five years, will result in higher service revenue in future periods once the initial twelve month warranty expires."
"We have been successful in increasing our cash flow. For the nine months, net cash provided by operating activities was $1.3 million, compared to $222,000 for the first nine months of fiscal 2012. Our cash position remains strong, even after payment of the special, one-time dividend in the 2013 second quarter. We are pleased with the financial results of the first nine months, and we expect to complete the year on a strong note," concluded Dr. Lehman.
On August 28, 2012, the Company completed the sale of the assets of its New Leaf business to Life Time Fitness, Inc. for $1.235 million. As a result, the Company has reclassified its results for prior periods to eliminate from its statement of comprehensive income (loss) all fiscal 2012 revenues and expenses associated with its New Leaf business and presented the income from New Leaf activities as "discontinued operations."
Net Operating Loss Carry Forward
At October 31, 2012, the Company had federal net operating loss carry forwards of approximately $14.5 million, not subject to IRC annual limitations on use. These loss carry forwards will expire in years 2018 through 2032.
The Company has scheduled a conference call for Thursday, August 29, 2013 at 4:30 p.m. ET to discuss its financial results for the third quarter of fiscal year 2013.
Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or listen via a live Internet webcast on the Company's website at www.mgcdiagnostics.com. A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code10032923, through September 5, 2013. A webcast replay of the conference call will be accessible on the Company's website at www.mgcdiagnostics.com for 90 days.
About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its subsidiary Medical Graphics Corporation, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.
Cautionary Statement Regarding Forward Looking Statements
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward−looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.Contact:
Wesley W. Winnekins
Joe Dorame, Robert Blum, Joe DiazMGC Diagnostics Corporation
Lytham Partners, LLCChief Financial Officer
(602) 889-9700(651) 484-4874
email@example.com(Financial Tables to Follow)
MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Balance SheetsJuly 31, 2013 and October 31, 2012(In thousands, except share and per share data)July 31,October 31,20132012Assets(Unaudited)Current Assets:Cash and cash equivalents
9,665Accounts receivable, net of allowance for doubtful accounts of $102 and $98, respectively6,7235,710Inventories, net of obsolescence reserve of $310 and $373, respectively3,8963,850Prepaid expenses and other current assets626568Total current assets20,07619,793Property and equipment, net of accumulated depreciation of $4,047 and $3,876, respectively 832578Intangible assets, net2,0711,492Other non-current assets—85Total Assets$
21,948Liabilities and Shareholders' EquityCurrent Liabilities:Accounts payable
2,094Employee compensation1,5171,749Deferred income2,6961,927Warranty reserve14691Other current liabilities and accrued expenses575442Total current liabilities6,4446,303Long-term liabilities:Long-term deferred income and other2,266895Total Liabilities8,7107,198Commitments and ContingenciesShareholders' Equity:Common stock, $0.10 par value, authorized 25,000,000 shares, 4,111,794 and 3,986,350 shares issued and 4,037,300 and 3,885,279 shares outstanding in 2013 and 2012, respectively
388Undesignated shares, authorized 5,000,000 shares, no shares issued and outstanding——Additional paid-in capital21,88521,046Accumulated deficit(8,019)(6,684)Total Shareholders' Equity14,26914,750Total Liabilities and Shareholders' Equity$
MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Statements of Comprehensive Income (Loss)(Unaudited in thousands, except per share data)Three Months endedNine Months endedJuly 31,July 31,2013201220132012RevenuesEquipment, supplies and accessories revenues
15,738Service revenues1,3171,0193,7223,1887,9286,89522,49918,926Cost of revenuesCost of equipment, supplies and accessories revenues3,1542,8358,9857,564Cost of service revenues3843541,0921,0863,5383,18910,0778,650Gross margin4,3903,70612,42210,276Operating expenses:Selling and marketing2,1522,1326,3725,558General and administrative9739133,6052,988Research and development5918251,8782,455Amortization of intangibles5112163293,7213,98211,87111,330Operating income (loss)669(276)551(1,054)Interest income—317Income (loss) from continuing operations before taxes669(273)552(1,047)Provision for taxes1773121Income (loss) from continuing operations652(280)521(1,068)Income from discontinued operations—147—277Net income (loss)652(133)521(791)Other comprehensive loss; net of taxUnrealized loss on securities———(2)Comprehensive income (loss)$
(793)Income (loss) per share:Basic From continuing operations
(0.28) From discontinued operations—0.04—0.07Total
(0.21)Diluted From continuing operations
(0.28) From discontinued operations—0.04—0.07Total
(0.21)Weighted average common shares outstanding:Basic4,0153,8473,9453,808Diluted4,0833,8474,0093,808Dividends declared per share$
MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Statements of Cash Flows(Unaudited in thousands)Nine Months Ended July 31,20132012Cash flows from operating activities:Net income (loss)
(791)Adjustments to reconcile net income (loss) to net cash provided by operating activities:Depreciation177182Amortization86329Stock-based compensation332269Increase (decrease) in allowance for doubtful accounts3(51)(Decrease) increase in inventory obsolescence reserve(63)70(Gain) loss on disposal of equipment(3)1Changes in operating assets and liabilities:Accounts receivable(1,016)1,289Inventories17(432)Prepaid expenses and other current assets27(315)Accounts payable(584)(435)Employee compensation(232)(114)Deferred income1,95032Warranty reserve55(47)Other current liabilities and accrued expenses22235Net cash provided by operating activities1,292222Cash flows from investing activities:Sales of investments—721Purchases of property and equipment and intangible assets(883)(730)Net cash used in investing activities(883)(9)Cash flows from financing activities:Dividends paid(1,805)—Proceeds from issuance of common stock under employee stock purchase plan12950Proceeds from the exercise of stock options48597Repurchase of common stock—(66)Repurchase of common stock upon vesting of restricted stock awards(52)(46)Net cash (used in) provided by financing activities(1,243)35Net (decrease) increase in cash and cash equivalents(834)248Cash and cash equivalents at beginning of period9,6658,461Cash and cash equivalents at end of period$
8,709Cash paid for taxes$
22Supplemental non-cash items:Current and non-current liabilities issued for leasehold improvements210—Common stock issued for long-term liability—42Accrued dividends51—
|SOURCE MGC Diagnostics Corporation|
Copyright©2012 PR Newswire.
All rights reserved